Asset Purchase Agreement, Milestone Payments Contingent Upon the Achievement of Certain Approvals

No definition available.

Name:	aeri_AssetPurchaseAgreementMilestonePaymentsContingentUpontheAchievementofCertainApprovals
Namespace Prefix:	aeri_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

[Line Items] for Organization, Consolidation and Presentation of Financial Statements [Table]

+ References

No definition available.

+ Details

Name:	aeri_OrganizationConsolidationandPresentationofFinancialStatementsLineItems
Namespace Prefix:	aeri_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of Dosage Designed to Reduce Elevated Intraocular Pressure

+ References

No definition available.

+ Details

Name:	aeri_PercentageofDosageDesignedtoReduceElevatedIntraocularPressure
Namespace Prefix:	aeri_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ References

No definition available.

+ Details

Name:	us-gaap_NumberOfOperatingSegments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ProductOrServiceAxis=aeri_RhopressaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=aeri_LatanoprostMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=aeri_EnvisiaTherapeuticsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

The Company The Company (Details) $ in Thousands		12 Months Ended
The Company The Company (Details) $ in Thousands	Oct. 04, 2017 USD ($) shares	Dec. 31, 2017 USD ($) Segment	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of business segments \| Segment		1
Research and development	$ 24,802	$ 72,078	$ 52,394	$ 44,451
Rhopressa
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Percentage of dosage designed to reduce elevated intraocular pressure		0.02%
Latanoprost
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Percentage of dosage designed to reduce elevated intraocular pressure		0.005%
Envisia Therapeutics Inc.
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Upfront cash payment	$ 10,500
Stock issued during period (in shares) \| shares	263,146
Stock issued during period, value	$ 14,300
Milestone payments contingent upon the achievement of certain approvals	$ 45,000